{"prompt": "['MC1752', '44', 'Definitions', 'Adverse Event', 'Any untoward medical occurrence associated with the use of a drug in humans, whether', 'or not considered drug related.', 'Suspected Adverse Reaction', 'Any adverse event for which there is a reasonable possibility that the drug caused the', 'adverse event.', 'Expedited Reporting', 'Events reported to sponsor within 24 hours, 5 days or 10 days of study team becoming', 'aware of the event.', 'Routine Reporting', 'Events reported to sponsor via case report forms', 'Events of Interest', 'Events that would not typically be considered to meet the criteria for expedited reporting,', 'but that for a specific protocol are being reported via expedited means in order to', 'facilitate the review of safety data (may be requested by the FDA or the sponsor).', '10.1', 'Adverse Event Characteristics', 'CTCAE term (AE description) and grade: The descriptions and grading scales found in the', 'revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be', 'utilized for AE reporting. All appropriate treatment areas should have access to a copy of the', 'CTCAE version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the CTEP web', 'site: (http://ctep.cancer.gov/protocolDevelopment/electronic: applications/ctc.htm)', 'a.', 'Identify the grade and severity of the event using the CTCAE version 5.0.', 'b. Determine whether the event is expected or unexpected (see Section 10.2).', 'c.', 'Determine if the adverse event is related to the study intervention (agent, treatment or', 'procedure) (see Section 10.3).', 'd. Determine whether the event must be reported as an expedited report. If yes, determine the', 'timeframe/mechanism (see Section 10.4).', 'e.', 'Determine if other reporting is required (see Section 10.5).', 'f.', 'Note: All AEs reported via expedited mechanisms must also be reported via the routine data', 'reporting mechanisms defined by the protocol (see Sections 10.6 and 18.0).', 'NOTE: A severe AE is NOT the same as a serious AE, which is defined in Section 10.4.', '10.2', 'Expected vs. Unexpected Events', 'Expected events - are those described within the Section 15.0 of the protocol, the study specific', 'consent form, package insert (if applicable), and/or the investigator brochure, (if an investigator', 'brochure is not required, otherwise described in the general investigational plan).', 'Unexpected adverse events or suspected adverse reactions are those not listed in Section 15.0 of', 'the protocol, the study specific consent form, package insert (if applicable), or in the investigator', 'brochure (or are not listed at the specificity or severity that has been observed); if an investigator', 'brochure is not required or available, is not consistent with the risk information described in the', 'general investigational plan.', 'Unexpected also refers to adverse events or suspected adverse reactions that are mentioned in the', 'investigator brochure as occurring with a class of drugs but have not been observed with the drug', 'Protocol Version Date: 21JUN2018']['MC1752', '45', 'under investigation.', 'An investigational agent/intervention might exacerbate the expected AEs associated with a commercial', 'agent. Therefore, if an expected AE (for the commercial agent) occurs with a higher degree of severity', 'or specificity, expedited reporting is required.', 'NOTE: *The consent form may contain study specific information at the discretion of the', 'Principal Investigator; it is possible that this information may NOT be included in the protocol or', 'the investigator brochure. Refer to protocol or IB for reporting needs.', '10.3', 'Attribution to agent(s) or procedure', 'When assessing whether an adverse event (AE) is related to a medical agent(s) medical or', 'procedure, the following attribution categories are utilized:', 'Definite - The AE is clearly related to the agent(s)/procedure.', 'Probable - The AE is likely related to the agent(s)/procedure.', 'Possible - The AE may be related to the agent(s)/procedure.', 'Unlikely - The AE is doubtfully related to the agent(s)/procedure.', 'Unrelated - The AE is clearly NOT related to the agent(s)/procedure.', '10.31 AEs Experienced Utilizing Investigational Agents and Commercial Agent(s) on', 'the SAME (Combination) Arm', 'NOTE: When a commercial agent(s) is (are) used on the same treatment arm as the', 'investigational agent/intervention (also, investigational drug, biologic, cellular product, or', 'other investigational therapy under an IND), the entire combination (arm) is then', 'considered an investigational intervention for reporting.', 'An AE that occurs on a combination study must be assessed in accordance with the', 'guidelines for investigational agents/interventions.', 'An AE that occurs prior to administration of the investigational agent/intervention must be', 'assessed as specified in the protocol. In general, only Grade 4 and 5 AEs that are unexpected', 'with at least possible attribution to the commercial agent require an expedited report, unless', 'hospitalization is required. Refer to Section 10.4 for specific AE reporting requirements or', 'exceptions.', 'An investigational agent/intervention might exacerbate the expected AEs associated with a', 'commercial agent. Therefore, if an expected AE (for the commercial agent) occurs with a', 'higher degree of severity or specificity, expedited reporting is required.', 'An increased incidence of an expected adverse event (AE) is based on the patients', 'treated for this study at their site. A list of known/expected AEs is reported in the', 'package insert or the literature, including AEs resulting from a drug overdose.', 'Commercial agent expedited reports must be submitted to the FDA via MedWatch 3500A', 'for Health Professionals (complete all three pages of the form).', 'http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048334.p', 'df', '10.32 EXPECTED Serious Adverse Events: Protocol Specific Exceptions to Expedited Reporting', 'For this protocol only, the following Adverse Events/Grades are expected to occur within this population and do', 'not require Expedited Reporting. These events must still be reported via Routine Reporting (see Section 10.6).*', '*Report any clinically important increase in the rate of a serious suspected adverse reaction (at your study', 'site) over that which is listed in the protocol or investigator brochure as an expedited event.', '*Report an expected event that is greater in severity or specificity than expected as an expedited event.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}